Claim Ledger
58% answered
Did management answer the analysts?
12 analyst questions audited, 3 evaded or deflected.
View Claim Ledger →
Divi's Laboratories — Q3 FY26
Divi's Laboratories reported Q3 FY26 PAT of ₹583 crore, broadly flat YoY, impacted by a one-time exceptional charge of ₹74 crore due to labor code changes.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Divi's Laboratories reported Q3 FY26 PAT of ₹583 crore, broadly flat YoY, impacted by a one-time exceptional charge of ₹74 crore due to labor code changes. Revenue mix improved with custom synthesis at 57% (9M), driving gross margin expansion as material consumption fell to 36.3% of sales (vs 39.8% YoY). Management highlighted strong volume traction in generics despite pricing pressure, and multiple CS projects progressing toward commercialization over the next year, with three dedicated facilities expected to start commercial volumes by Q3-Q4 CY2027. The peptide segment continues to advance, with a dedicated commercial building for large-scale SPS reactors now in validation. Backward integration at Unit 3 is supporting margins and freeing up GMP capacity. Key risk: pricing pressure in generics may persist longer than expected, limiting value growth.
डिवीज लैबोरेटरीज ने Q3 FY26 में ₹583 करोड़ का मुनाफा कमाया, जो पिछले साल के लगभग बराबर है। इसमें ₹74 करोड़ का एक बार का खर्च शामिल है, जो मजदूरी नियमों में बदलाव के कारण हुआ। कंपनी की कमाई का 57% हिस्सा कस्टम सिंथेसिस (ग्राहकों के लिए खास रसायन बनाना) से आया, जिससे मुनाफा बढ़ा। कच्चे माल की लागत घटकर बिक्री का 36.3% रह गई (पिछले साल 39.8% थी)। कंपनी ने कहा कि जेनेरिक दवाओं की बिक्री अच्छी है, भले ही कीमतों पर दबाव हो। अगले साल तक कई नए प्रोजेक्ट शुरू होंगे और तीन नए कारखाने 2027 के अंत तक उत्पादन शुरू कर देंगे। पेप्टाइड (एक तरह की दवा) सेगमेंट भी आगे बढ़ रहा है। जोखिम: जेनेरिक दवाओं पर कीमत का दबाव लंबे समय तक रह सकता है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Persistent generic pricing pressure
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Custom Synthesis Revenue Mix (9M)
56%
+4pp YoY
Custom synthesis share of total sales increased from 52% to 56% in 9M FY26, driving margin improvement.
Material Consumption Ratio (Q3)
36.3%
-350bps YoY
Material cost as a percentage of sales improved sharply YoY, reflecting better product mix and backward integration benefits.
Domestic Supplier Base
78%
N/A
Procurement from domestic suppliers increased to 78%, reducing China dependency amid export tax rebate changes.
Capacity Utilization (CS segment)
70-80%
N/A
Current capacity utilization in custom synthesis ranges 70-80%, with flexibility to ramp up for new commercial volumes.
What Changed vs Last Quarter
NEW
Three dedicated CS projects to commercialize by Q3-Q4 CY2027
Three custom synthesis dedicated facilities are expected to start commercial volumes in the second half of calendar 2027, pending customer regulatory approvals.
NEW
Double-digit constant currency growth trajectory maintained
Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline of late-lifecycle and new product launches.
NEW
Capex to remain at historical run-rate excluding dedicated projects
Excluding the three dedicated CS projects, capex is expected to be approximately in line with historical levels, with Phase 2 expansion at Unit 3 under evaluation.
DROPPED
Capex for FY26 to exceed ₹2,000 crore
Management indicated that capex spend in H1 was ₹1,550 crore and full-year capex will be higher than the earlier guidance of ₹2,000 crore.
DROPPED
Three major capex programs with long-term supply commitments
Three projects are at various stages (installation, qualification, validation) and expected to contribute revenue in 1-2 years, subject to regulatory approvals.
DROPPED
Constant currency revenue growth ~10-11% for FY26
Management expects constant currency growth for the full year to be similar to H1's 10.79%.
DROPPED
Generic pricing pressure to persist for next 2 quarters
Management does not foresee improvement in generic pricing for at least the next two quarters.
NEW RISK
China export tax rebate withdrawal impact on input costs
China's removal of export tax rebates on certain chemicals may increase raw material costs, though management has diversified 78% of procurement domestically.
NEW RISK
Regulatory approval delays for CS commercial volumes
Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could slip beyond the targeted Q3-Q4 CY2027 timeline.
NEW RISK
Dependence on a few large CS molecules
While management claims a diversified basket, the three dedicated projects represent significant investment; any single project delay could impact near-term revenue visibility.
RISK GONE
Regulatory delays in new project validations
Commercialization of three major capex projects depends on regulatory approvals (EU, US), which could be delayed, pushing revenue contribution beyond 1-2 years.
RISK GONE
Competition from new CDMO entrants
Analyst raised concern about increased competition in custom synthesis from Indian players; management acknowledged but emphasized long-term relationships and non-price factors.
RISK GONE
US tariff impact on raw material costs
Management noted potential cost increases from US tariffs on Chinese suppliers and Russia sanctions, though mitigated by inventory and diversified sourcing.
Fast read
Guidance and risk preview
Three custom synthesis dedicated facilities are expected to start commercial volumes in the second half of calendar 2027, pending customer regulato...
Pricing environment in generics remains competitive, limiting value growth despite volume increases.
View Risks →